We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals

78.85 USD
+2.71
3.56%
At close Updated Sep 21, 4:00 PM EDT
Pre-market
After hours
77.31
-1.54
1.95%
1 day
3.56%
5 days
11.23%
1 month
4.64%
3 months
-2.15%
6 months
6.67%
Year to date
0.54%
1 year
-17.8%
5 years
161.96%
10 years
21.08%
 

About: ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Employees: 970

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 30.4%
Neutral 52.2%
Negative 17.4%
Neutral
Seeking Alpha
7 days ago
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
18 days ago
ANI Pharmaceuticals to Present at September Investor Conferences
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:
ANI Pharmaceuticals to Present at September Investor Conferences
Neutral
GlobeNewsWire
28 days ago
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
Negative
Zacks Investment Research
1 month ago
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
Positive
Zacks Investment Research
1 month ago
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Negative
Zacks Investment Research
1 month ago
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
Negative
Benzinga
1 month ago
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported upbeat earnings for the second quarter on Friday.
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
Neutral
Seeking Alpha
1 month ago
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
Neutral
MarketBeat
1 month ago
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.
ANI Pharmaceuticals Q2 Earnings Call Highlights
Price charts implemented using Lightweight Charts™